Skip to main content

Fukushima Thyroid Examination Fact Sheet: September 2017 (Long Version)

Fukushima Thyroid Examination Fact Sheet:  September 2017

✴Copying or re-posting part or whole of this post is not permitted. Please link to this post instead.

Note: Corrections were made in the following paragraphs in pink color on October 17, 2017.
Second paragraph in section "Screening protocol"
First paragraph in section "Thyroid cancer cases"
First paragraph in section "Transparency and integrity of data"
Second paragraph in subsection "1. A limited time interval after the accident" in section "Official stance on radiation effects"
Fourth paragraph in subsection "2. Very low doses" in section "Official stance on radiation effects"

Note: A shorter version of this fact sheet has been e-published on the website of Kagaku by the Iwanami Publishers. It can be downloaded from this linkCitation in AMA style is as follows: Hiranuma Y. Fukushima thyroid examination fact sheet: September 2017. Kagaku. 2017;87(9):e0001-e0011.

This fact sheet reviews the current status of the Thyroid Ultrasound Examination (TUE) in Fukushima Prefecture. In its seventh year, all the data and information from the TUE have become quite large and complex. Drawing from official meetings, documents, data and publications—some available only in Japanese, some only in English, this fact sheet is intended to act as an English overview.

On October 9, 2011, Fukushima Prefecture began the TUE on about 360,000 residents who were age 18 or younger at the time of the March 11, 2011 Fukushima nuclear accident. As the exposure to radioactive iodine dramatically increased the incidence of pediatric thyroid cancer after the 1986 Chernobyl nuclear accident, the TUE was implemented to monitor the exposed children in Fukushima Prefecture. The majority of Fukushima residents did not receive iodine tablets for protection of their thyroid glands.

The TUE is conducted as part of the Fukushima Health Management Survey (FHMS),[1]  comprising the Basic Survey and the Detailed Surveys. The Basic Survey estimates external radiation exposure dose for the first four post-accident months from behavior questionnaires. The Detailed Surveys consist of the TUE, Comprehensive Health Check, Mental Health and Lifestyle Survey, and Pregnancy and Birth Survey. The study protocol for the FHMS was published in 2012.[2] The FHMS is funded by the central government[3] and commissioned by the prefectural government to the prefectural-run Fukushima Medical University (FMU).[4]

Screening protocol
The TUE, conducted every 2 years up to and every 5 years beyond age 20, consists of the primary and confirmatory examinations. The primary examination uses thyroid ultrasound screening to detect cysts and/or nodules. Cysts and nodules that meet certain diagnostic criteria (category B and above, as explained later) are recommended to undergo the confirmatory examination for more detailed ultrasound examination including Doppler ultrasound and elastography as well as urine and blood testing. Suspicious cases undergo fine-needle aspiration cytology (FNAC) to examine thyroid cells for signs of malignancy. FNAC positive cases are followed by surgery or observation. Definitive diagnosis of thyroid cancer requires pathological examination of surgically excised thyroid tissue. Thus the TUE results are reported as the number of suspected or confirmed of cancer cases. (Note: So far there has been only one case—early in the screening process—that turned out to be benign after surgery).

The first round was expected to produce a baseline[i] for this population due to a supposed latency of 4 years for radiation-induced thyroid cancer in children based on the Chernobyl data. There has been no thyroid cancer screening of similar magnitude and quality in unexposed children in Japan to compare to. Thus the first round screening was called “Initial Screening” at first and later renamed “Preliminary Baseline Screening (PBLS).” The second and third rounds are called “First Full-Scale Screening” and “Second Full-Scale Screening,” respectively.

The first round[5] of the TUE was scheduled to be conducted from October 9, 2011 through March 31, 2014, with each fiscal year—from April through the following March—covering residents from a set of municipalities grouped in a descending order of the air dose level of radiation. In order to boost the participation rate (by 1.5% to 81.7%), the first round was continued through April 30, 2015, concurrent with the first year of the second round. This meant that first time participants were still being registered for the first round while others were already going through the second round.[ii]

The second round
[6] began in April 2014, immediately after the first round supposedly completed and included residents who were born between April 2, 2012 and April 1, 2013.[iii] The primary examination of the second round, with a participation rate of 71.0% and progress rate of 100.0%, is essentially complete. But the confirmatory examination, with a participation rate of 82.3% and progress rate of 95.4%, is still ongoing.

The third round[7] began on May 1, 2016 and is scheduled to run through March 2018—the end of Fiscal Year 2017. As of March 31, 2017, 120,596 out of the survey population of 336,616 residents—about 45,000 fewer than previous rounds as the milestone screening participants are excluded[iv]—have participated in the ongoing primary examination at a participation rate of 35.8%. The confirmatory examination began on October 1, 2016 with a participation rate of 48.0% and progress rate of 67.8% so far. 

The unique diagnostic categories of A1, A2, B and C for the TUE were established by the "Sectional Meeting for Considering the Diagnostic Criteria of the Thyroid Ultrasound Examination” (referred as the Diagnostic Criteria Subcommittee[v] from here in). These diagnostic categories are: 
  • A1: no nodules or cysts found
  • A2: nodules 5.0 mm or cysts[vi] 20.0 mm
  • B: nodules 5.1 mm or cysts 20.1 mm
  • C: requiring immediate confirmatory examination

The A1 and A2 categories are followed in the subsequent round of screening two years later. The B and C categories require confirmatory examination. There has only been one case of the C category which requires confirmatory examination immediately.

Results of the Thyroid Ultrasound Examination
English translation of the results are found on the website of the Office of International Cooperation, Radiation Medical Science Center, Fukushima Medical University.[8] (Note: Shunichi Yamashita is listed as Founding Senior Director of Radiation Medical Science Center for Fukushima Health Management Survey).

The most current official summaries in English are found in Chapters 14 and 15 of “Thyroid Cancer and Nuclear Accidents,” a book featuring presentations from the “Fifth International Expert Symposium in Fukushima on Radiation and Health: Chernobyl+30, Fukushima+5: Lessons and Solutions for Fukushima’s Thyroid Question” held in Fukushima City on September 25-26, 2016.[9],[10] Though the most current official version in print, these reports are missing some information—some too new to be included (ex: additional cancer cases) and some that should have been reflected (ex: solid variant PTC).

The primary examination results show an increasing proportion of the A2 category from the first (47.8%) to the second round[6] (59.0%) as well as in the successive fiscal year cohort within each round (36.4% to 44.6% to 55.5% in the first round and 57.4% to 61.2% in the second round). The ongoing third round screening shows an A2 proportion of 64.5% so far.[7] The proportion of B is the same in the first and second rounds at 0.8%.

Thyroid cancer cases
The report of the first cancer case was documented in the minutes of the proceeding[11] at the Eighth Oversight Committee meeting held on September 11, 2012,[12] exactly eighteen months after the accident. After the first reporting of the FNAC results on June 5, 2013,[13] subsequent reports revealed an increasing number (14 to 16 more each time) of malignant or suspicious cases for about a year with the number of surgically confirmed cancer cases lagging behind. The first 4 cancer cases from the second round were reported on December 25, 2014.[14] At present, the second round results are yet to be finalized due to the still ongoing confirmatory examination, but the most recent data released on June 5, 2017,[6] show 71 suspected cancer cases including 49 cases surgically confirmed. The current third round screening, called “Second Full-Scale Thyroid Screening,” has so far detected 4 suspected cancer cases with 2 cases surgically confirmed.[7] 

The latest results
Table 1 shows the most recent results reported on June 5, 2017.[15]

Table 1: The latest results (data as of March 31, 2017)
*Includes a single case of benign nodules

Transparency and integrity of data
Once the confirmatory examination reveals the need for a closer clinical follow-up, FNAC and/or surgery, the case is no longer part of the TUE and enters regular medical care under the national health care system. On the premise that “disclosure of clinical information is prohibited in principle,” most data from such “follow-up” cases are not shared with the Oversight Committee or Fukushima residents. However, FMU researchers have allowed themselves to disclose such clinical information at academic meetings and in medical journals. 

Recently it became known that FMU has not publicized all cancer cases, let alone details, because only cancer cases diagnosed directly during the confirmatory examination are reported to the Oversight Committee. This came to light in March 2017 when an unreported cancer case was discovered in a boy who was 4 at the time of the accident.[16] FMU explains that cases followed up under regular medical insurance are deemed outside the boundaries and responsibilities of the TUE, with no obligation or actual system to collect such data for reporting.[17] The actual number of follow-up cases is uncertain due to potential duplicates in the subsequent rounds, but about 1,250 cases have been followed up from the first round. There is no way to know how many cancer cases might have been diagnosed in this group, if any.

This means the FMU studies[18],[19] using the official, incomplete data lack scientific integrity.

Surgical and pathological features 
Due to the reasons explained above, surgical and pathological details of the cases are not readily available. The most detailed and updated—albeit incomplete—surgical and pathological information on 125 cases operated at FMU, has been published in the aforementioned book, “Thyroid Cancer and Nuclear Accidents.” (The presentation slides can be downloaded from the Radiation Medical Science Center website[20] and information on the slides is explained in detail on the author’s blog post[21]).

Of 125 cases, 121 (96.8%) were ipsilateral and 4 (3.2%) were bilateral. Hemithyroidectomy was conducted in 114 cases (91.2%) while 11 cases (8.8%) underwent total thyroidectomy.[vii] All cases underwent the central lymph node dissection, and 24 cases also had dissection of the lateral neck lymph nodes (20 unilateral and 4 bilateral). The intraoperative nerve monitoring system (IONM) was used in all cases to prevent recurrent laryngeal nerve (RLN) injury.

There were no surgical complications such as hypoparathyroidism, permanent RLN palsy, or postoperative bleeding. One case had persistent RLN palsy despite the use of the IONM system.

Histopathological diagnosis showed 121 cases (96.8%) of papillary thyroid cancer (PTC), 3 cases of poorly differentiated thyroid cancer (PDTC), and 1 case of thyroid cancer categorized as “other” in Japan’s thyroid cancer management guideline. Subtypes of 121 PTC included 110 classical variants, 4 follicular variants, 3 diffuse sclerosing variants and 4 cribriform morula variants associated with familial adenomatous polyposis. A special mention was made that no case of solid variant of PTC was found. Absence of solid variant PTC has been allegedly one of the distinguishing points between Fukushima and Chernobyl cases.

However, the Supplemental Report of PBLS5 released on June 6, 2016 revealed the fact that 2 of 3 PDTC cases—one each from FY2011 and FY2012—were reclassified as PTC in accordance with the November 2015 revision of Japan's thyroid cancer diagnostic guidelines. Definition of PDTC in the previous guidelines included the solid variant of PTC, unlike the World Health Organization (WHO) classification of Tumors of Endocrine Organs. FMU has yet to specify PTC subtypes of the 2 reclassified cases, and Suzuki inexplicably neglected to mention the reclassification of 2 PDTC cases during the September 2016 symposium.

Existence of the solid variant PTC in Fukushima is confirmed in a recent study (in Japanese) by Suzuki et al., “Ultrasound findings of childhood thyroid cancer”[22] that covers childhood thyroid cancer cases treated at FMU including cases diagnosed during the TUE: “Cases previously classified as poorly differentiated thyroid cancer in the Sixth Edition of Thyroid Cancer Management Guidelines are reclassified as solid variant PTC in the Seventh Edition. Solid variant PTC is known to be not uncommon in pediatric thyroid cancer cases in Japan, but there have been extremely few cases operated in Fukushima at this time.”

Table 2: Pre-operative (clinical) and post-operative (pathological) TNM findings[viii]
(T=tumor size, N=lymph node metastasis, Ex=extrathyroidal extension, M=distant metastasis)

The post-operative TNM classification (Table 2) shows about 60% of tumors with a diameter of 20 mm or less (pT1a & pT1b), 78% with lymph node metastasis (pN1a & pN1b), and 39% with cancer cells spreading outside the thyroid (pEx1).[ix] Of 44 microcarcinoma cases (cT1a cN0 M0), 33 had surgical indications such as suspicion of extrathyroidal extension (20), lymph node metastasis (1), RNL invasion (10), tracheal invasion (7), Graves disease (1), and ground-glass opacity of lungs (1).[x] Of these, 3 cases turned out to be pT1apN0pEx0, justifying surgery in 30 cases. Of 11 cases which opted for surgery against the recommendation of non-surgical observational follow-up, 2 turned out to be pT1a pN0 pEx0. Details of 3 cases with lung metastasis (M1) are: 1) male age 16 at exposure, cT3 cN1a, pT3 pN1a; 2) male age 16 at exposure, cT3 cN1b, pT2 pN1b; and 3) female age 10 at exposure, cT1 cN1b, pT3 pN1b pEx1.

Other thyroid cancer data
A direct comparison between the prevalence obtained by screening of the asymptomatic population and the incidence based on clinical diagnosis is considered inappropriate. However, as a reference, the 2012 national incidence estimated in Japan for thyroid cancer in ages 0-19 was 4.6 per million for both sexes, 1.4 per million for male, and 7.9 per million for female.[23] 

Assuming all the suspicious FNAC cases are to be confirmed as cancer, excluding the single case surgically confirmed to be a benign nodule, the first round screening data yields thyroid cancer prevalence of 386 per million (116 cancer cases per 300,473 participants) for both sexes in those who were 0-18 years old at the time of the accident.

Table 3: 2012 Thyroid cancer incidence rate in Japan by age and sex (per million)

In t
he so-called “3-prefecture study,[xi]” thyroid ultrasound screening was conducted on 4,365 children aged 3-18 in Aomori, Yamanashi and Nagasaki Prefectures.[24] Findings of similar proportions of cysts and nodules[24] to the TUE and one cancer case[25] in 4,365 led the officials to hail the 3-prefecture study as a control study: the TUE results were declared “about the same as other unexposed areas in Japan.” However, the 3-Prefecture Study is an inappropriate control due to unmatched age range and sex distribution as well as the small size of the study cohort leading to a high margin of error.[26] A single case of thyroid cancer diagnosed in the 3-prefecture study makes a point estimate of 229 per 1 million with a 95% confidence interval of  6 to 1,276 per million,[27] but the wide bound of the confidence interval weakens the meaningfulness of the point estimate.

Tsuda et al. published in October 2015, the first epidemiological analysis of the publicly available thyroid cancer data (the first round screening data as of December 31, 2014) in Epidemiology, the official, peer-reviewed journal of the International Society for Environmental Epidemiology.[28] They found a regional variability of the prevalence within Fukushima Prefecture as well as increased incidence rate ratios in most of Fukushima Prefecture compared to the national incidence rate. Despite the claim by the authors that the study used standard epidemiological methods based on modern epidemiology, it generated seven criticisms[29],[30],[31],[32],[33],[34],[35] and an authors’ response.[36]  

The National Cancer Center research shows the observed/expected ratio of thyroid cancer prevalence to be as much as 30.8,[37] attributing this increase to overdiagnosis.

Official stance on the high prevalence of thyroid cancer
FMU officials claim that the high prevalence of thyroid cancer diagnosed in Fukushima Prefecture is not excess occurrence but excess detection due to screening of asymptomatic individuals by highly sensitive ultrasound equipment, i.e. screening effect. As early as February 2013 officials began to use the term, “screening effect” and suggested that Fukushima cases constituted diagnosis of indolent “latent” cancer that would not cause any symptoms until much later date, i.e. overdiagnosis.

The National Cancer Center researchers say the high number of thyroid cancer cases detected during the first round is “difficult to explain by screening effect alone” in a document[xii] submitted to the Thyroid Examination Evaluation Subcommittee in November 2014.[38]  Shoichiro Tsugane and Kota Katanoda estimated the 2010 (pre-accident) prevalence of thyroid cancer in ages 0-18 in Fukushima Prefecture from available data. The estimated prevalence was then compared with the first round results of 104 suspected and confirmed thyroid cancer cases at the time: The first round results were 61 times the estimated prevalence before the Fukushima accident. This increase was attributed to either excess occurrence due to some unknown reason or overdiagnosis, and not explainable by screening effect alone.

Researchers claiming screening effect and/or overdiagnosis do not appear to take clinical characteristics of these cancer cases into consideration. Perhaps defending validity of surgery, Suzuki refrains from claiming overdiagnosis, yet he does attribute the high number of thyroid cancer cases diagnosed to screening itself. Screening effect presupposes the cancer cases would not have been discovered until much later date, but aggressive features of even microcarcinoma (≤10 mm in diameter) make this a weak argument.

Prior diagnostic status of the newly diagnosed cancer cases
For 71 suspected cancer cases found during the second round screening, their first round results were: 33 A1, 32 A2 (7 nodules and 25 others such as cysts), 5 B, and one case that did not undergo the first round. The 58 cases (33 A1 and 25 non-nodular A2) which had no lesions with malignancy potential suggest a few possibilities: 1) missed diagnoses; or 2) rapid growth of cancerous lesions in 2-3 years since the first round screening, contradicting the known latency of 4 years for childhood thyroid cancer.

The official explanation is neither.

Akira Ohtsuru, the head of the TUE, states no missed diagnosis was confirmed when prior ultrasound images were reviewed. (This claim has not been independently verified). He rejects the notion of rapid growth, insisting that these are not “newly formed” but “newly detected.” His explanations—officially documented in the minutes of the proceedings[39]—are that even though some of the small nodules are very easy to detect by ultrasound, exceptions arise when 1) the border of the lesion is ambiguous, 2) the density of the lesion is so low that it blends into the normal tissue, or 3) the lesion resembles the normal tissue. Thus, the nodules were simply not detected even though they were there. Ohtsuru said that when such previously undetected nodules grow relatively large enough to become detectable by ultrasound, they might look as if they suddenly appeared. (This suggests a possibility that other “newly detected” cancer cases might exist at a similar proportion amongst individuals who received A1 or A2 assessments in the first round and elected not to participate in the subsequent rounds. Such cases would not be in the official count). Ohtsuru added that nodules that have already been detected by ultrasound do not to appear to grow very rapidly in general.

An issue of the sex ratio
For thyroid cancer, the female to male ratio is nearly 1:1 in the very young, but it is known to increase with age[40],[41] and decrease with radiation exposure.[42] The overall female to male ratio was 1.97:1 and 1.22:1 in the first and second round, respectively, both much lower than most recent clinically observed ratio of 7.9:1.[43] Curiously, the FY2015 municipalities have consistently shown a higher number of males than females with the overall female to male ratio of 1:1.38, but this has not been officially investigated.

In February 2017, after explaining that the cancer registry showed the female to male ratio close to 1:1 up to around puberty and the autopsy data showed the female to male ratio of 1:1 or smaller in adults, Ohtsuru concluded, “It is scientifically expected that thyroid cancer screening in general leads to a smaller female to male ratio even in adults.”[39]

His “scientific” explanation does not hold up. An analysis of the cancer registry data from 2000 to 2012 shows the female to male ratio up to puberty is closer to 2:1 than 1:1 (Table 4). Validity of extrapolation from autopsy data to screening is highly questionable, and there is no evidence to show thyroid cancer screening will yield a smaller female to male ratio as evident in the thyroid cancer incidence from South Korea[44] where active screening increased the incidence of thyroid cancer (Table 5).

Table 4: Thyroid cancer incidence calculated from the 2012 national incidence estimates in Japan[23]

Table 5: Incidence by sex and age group in South Korea compiled from supplementary tables 2&3 in Ahn et al.[44] (per 100,000)

Official stance on radiation effects 
FMU’s stance is summarized in the following excerpt[9]:

The relationship between a high prevalence of thyroid cancer and radiation exposure is thought to be very unlikely because of several standpoints; e.g., a limited time interval after the accident, very low doses, age and geographic distributions of thyroid cancer patients, driver mutation patterns, and pathological characteristics. This finding suggests overdiagnosis due to screening effects over the past 5 years.

This statement is inconsistent and contradictory. By “over the past 5 years” officials are clumping the first and second rounds together, contradicting their own assertion that the first round is the baseline.

Each of the official claims, 1) a limited time interval after the accident, 2) very low doses, 3) age distribution, 4) geographic distribution, 5) driver mutation patterns, and 6) pathological characteristics, is separately reviewed below.

1.    A limited time interval after the accident
This means the latency of 4-5 years would not have allowed radiation-induced thyroid cancer to appear during the first round.

The minimum latency for all childhood cancers other than lymphoproliferative and hematopoietic cancer has been determined as 1 year in “Minimum Latency & Types or Categories of Cancer,”[45] a policy document used by the Center for Disease Control in the World Trade Center Health Program (accessible from the website, The document also establishes 2.5 years as minimum latency for thyroid cancer in adults.

The common notion of radiation carcinogenesis focuses on radiation-induced DNA damage leading to mutations, and “radiation-induced” cancer refers to carcinogenesis “initiated” by radiation. However, radiation is considered a “complete carcinogen”, i.e. able to both initiate and promote cancer development.[46],[47] In reality it is difficult to completely separate initiation from promotion and progression since radiation-induced DNA damage can activate myriad pathways that result in genomic instability and may be involved in multiple stages of carcinogenesis.[46]

Even Otsura Niwa, the current chairman of the Radiation Effect Research Foundation, suggested in 1995 that “radiation induces cancer by enhancement of the spontaneous carcinogenesis process” and that “the first step of radiation carcinogenesis may not be the direct induction of mutation.”[48]

Ionizing radiation meets at least three of ten key characteristics of carcinogen as defined by the International Agency for Research on Cancer: 1) genotoxic, 2) altering DNA repair or causing genomic instability, and 3) inducing oxidative stress.[49] Oxidative stress produces ROS which are known to contribute to the bystander effect extracellularly and also intracellularly.[50] Thus carcinogenic characteristics of radiation by definition include both genetic and non-targeted effects. Induction of oxidative stress leads to cellular injury, affecting the microenvironment.

It has been proposed from the systems biology perspective that non-targeted radiation effects create the critical context that promotes cancer development by influencing the microenvironment.[51],[52]

It is then plausible to consider that some, if not all, of the thyroid cancer cases in Fukushima may be the result of radiation exposure via promotion of preexisting premalignant cells into malignancy, which constitutes a radiation effect in a broad sense. This in turn invalidates the notion of the first round as the baseline without the radiation effects.

2.    Very low doses
While the total radiation exposure doses in Fukushima may be lower than in Chernobyl, it is crucial to recognize that thyroid exposure doses in Fukushima are not known for the majority of residents due to insufficient direct measurements and estimated doses are underestimated on many levels. Officials use direct measurements in 1080 children (so-called the 1080 survey)[53] to show “how low the doses were,” but what is hardly ever discussed are the conditions for these measurements to lead to underestimation. The 1080 survey 1) used equipment with low sensitivity , 2) was conducted after the half-life of radioactive iodine 131 passed, 3) was conducted in the high background levels, and 4) subtracted the radiation level at the individual shoulder—rather than the air dose level—as the background level from the actual measurement, potentially leading to oversubtraction.[54] High readings were never confirmed with a more sensitive thyroid counter“ so as not to create worries for and discrimination against the individual, family, and communities.”[55],[xiii] Besides, the sample size of 1080—only 0.3% of about 360,000 Fukushima residents who were 18 or younger in March 2011—can hardly be considered to be representative of the whole cohort. Individual dose reconstruction is difficult at this point due to a short half-life of iodine 131. More detailed diet and behavior history from individuals diagnosed with thyroid cancer would be helpful, but it has not been done.

Also, the possibility that residents ingested highly contaminated food and water cannot be eliminated. Contrary to the official claim that milk and other foodstuffs were swiftly banned,[56] the central government did not establish the provisional regulatory limits for food until March 17, 2011, six days after the accident. Meanwhile, raw milk collected in Kawamata Town, Fukushima Prefecture showed radioactive iodine levels of 1190 Bq/kg on March 16 and 1510 Bq/kg on March 17, far exceeding the provisional regulatory limits for milk/milk products of 300 Bq/kg.[57] However, the test results of the Fukushima raw milk as well as the Ibaraki spinach were not publicized until March 19, 2011.[58]

Officials also claim the exposure doses were low in general due to swift evacuation and indoor sheltering orders by the government, but evacuation did not always go as swiftly as officially recognized, and actual exposure doses depended on the timing and direction of evacuation.[59],[60] The post-earthquake water outage led many families outside to seek out water rations rather than staying indoor without any forewarning against the approaching radioactive plume.

Shunichi Yamashita is one of the officials known to emphasize that “the excess risk of solid cancer is not statistically significant, especially below 100 mSv.”[61] However, a growing body of evidence supports the fact that there is no threshold dose below which radiation has no effect and health effects are seen at much lower doses than 100 mSv.[62],[63],[64],[65],[66],[67],[68] (Addendum: The contextual picture  of the so-called 100 mSv threshold discourse as it relates to the thyroid cancer issue is discussed in “Ethical Issues Related to the Promotion of a “100 mSv Threshold Assumption” in Japan after the Fukushima Nuclear Accident in 2011: Background and Consequences” by Tsuda et al).

It is also important to note that the majority of children in Fukushima did not receive iodine tablets to mitigate the effect of radioactive iodine isotopes, mainly iodine 131, on their thyroid glands. High iodine diet in Japan is considered to reduce uptake of radioactive iodine and thus thyroid cancer risk, but actual urinary iodine levels in children show 16.6% with mild to moderate iodine deficiency.[69] A higher risk for iodine deficiency was seen in ages <6 and 12-18, mostly reflecting age groups outside the school lunch program. Furthermore, the lack of iodine supplementation in the infant formula in Japan means a higher risk in the already vulnerable population.

Another factor that is frequently overlooked is the contribution from short-lived radionuclides that potentially affect the thyroid, such as iodine 132/tellurium 132 and iodine 133.[59]

3.    Age distribution
Ohtsuru et al. state, “In the early phase of the Chernobyl accident, the increased number of thyroid cancer cases was predominantly among younger children, especially those aged 0-4 years at the time of the accident; thus, the age distribution we observed was completely different (Williams, 2015; Takamura et al., 2016). Therefore, it can be concluded that the lesions identified during the two cycles of the examination over the past 5 years represent the natural incidence in a young population when ultrasound screening is used as a detection methodology.”

There are a few issues with this statement. It is true that the average age for Fukushima’s thyroid cancer cases from the first round is 14.9 years, and 62% were ages 15 or older at exposure. Takamura et al. state,[70] “starting from 1990, the incidence of thyroid cancer increased greatly in children who were aged 0–5 years at the time of the accident, which suggests that this age group is particularly vulnerable to the effects of radiation.” Official have stated multiple times that Fukushima’s thyroid cancer cases were not due to radiation exposure because those aged 0-5 at exposure were not diagnosed.[71]

When a 5-year-old (at exposure) boy was diagnosed with thyroid cancer during the second round, officials dismissed that a single case didn’t mean anything. Now the officials are shifting the number from ages 0-5 to 0-4 years, as evident in the excerpted statement by Ohtsuru et al. (Actually, an “unofficial” thyroid cancer case in a 4-year-old at exposure has surfaced,19 but the case is not included in the official count and remains unacknowledged by officials).

Next issue is an inappropriate data comparison. “In the early phase of the Chernobyl accident” actually should say “beginning four years after the Chernobyl accident” when thyroid cancer cases began to skyrocket in ages 0-5 at exposure. Fukushima’s TUE began 7 months after the accident, while in Chernobyl no organized screening activities were conducted during the first several years. Williams used a graph of the number of thyroid cancer cases by age in Chernobyl in an unspecified time span superimposed with that in Fukushima during the first 3 years after the accident.[72] Takamura et al. used 2 separate graphs, one showing thyroid cancer surgical cases in Belarus during different time periods after the Chernobyl accident and another showing the age distribution of the Fukushima cases during the first 3 post-accident years.[xiv]

Comparing data from different time periods in this manner is unscientific and misleading. Actually, It’s not surprising that the age distribution was “completely different” in both examples. When similar post-accident periods were compared in a correspondence to Thyroid, the age distribution of cancer cases in Fukushima was described as “strikingly similar” to that in Ukraine.[73]

To conclude that the absence of ages 0-5 in Fukushima thyroid cancer cases during the first 3-4 post-accident years when there was no increase in that age group in Chernobyl is at best illogical[74] and actually contradicts the official designation of the first 3-4 post-accident years as latency period.

4.    Geographic distribution
The FMU study[19] suggested no geographical differences after “no significant association between the individual external doses and thyroid cancer prevalence” was found. However, this study suffers from inadequate or inappropriate study designs, an inappropriate geographical classification[xv] and a misleading reliance on the external doses.[xvi]

It is the thyroid dose, not the external dose, that is of concern in evaluating the thyroid cancer risk, and relying on the external doses is simply misleading. Furthermore, their external dose classification, purportedly “generally consistent” with the WHO 2013[75] classification, amplifies the problem: The study includes municipalities wholly or partly in the 20 km zone in the middle dose area, while thyroid doses in the WHO 2013 excludes the 20 km zone. UNSCEAR 2013 shows some thyroid dose estimates in the 20 km zone to be higher than some municipalities designated as the “middle dose area.”[76],[77]

Further, inclusion of Iwaki City in the lowest dose group is inappropriate because the estimated thyroid dose in Iwaki City is as high as that in the highest dose group such as Iitate Village or Kawamata Town. In fact, the highest thyroid dose from the 1080 survey was found in a child from Iwaki City.[59] Located 40 km south of the FDNPP outside the evacuation or indoor sheltering zones, Iwaki City was hit with the radioactive plume in the early morning hours of March 15, 2011, with the highest radiation reading at 23.72 µSv/hr. However, very little rainfall resulted in low ground deposits of radionuclides,[78] leading to low external doses. Thus, Iwaki City’s thyroid doses are incongruous with external doses.The fact Iwaki City was chosen for thyroid survey to directly measure radioactive iodine contents of the thyroid should speak for itself, except only a fraction of children in Iwaki City (134 of 49,429 or 0.3%) actually went through the direct measurements with a survey meter.

For the first round results, FMU officials divided the entire prefecture into four geographical regions (the evacuation zone plus other 3 geographical regions of Hamadori, Nakadori and Aizu) and reported no regional differences in the proportion of suspected or confirmed cancer cases from the first round (Table 9 of the PBLS report[5]). However, this analysis is not very meaningful due to lack of age adjustment and a weak relationship between the regional division and exposure doses.

Meanwhile, an independent analysis of the second round data reveals a lower rate of thyroid cancer—age-adjusted and statistically significant—in the less exposed FY2015 cohort (excluding Iwaki City) compared to the more exposed FY2014 cohort.[79] For cancer cases with estimated external doses, a significant difference was found between < 1 mSv and ≥ 1 mSv: the rate of cancer in the ≥ 1 mSv group was more than twice as large as the < 1 mSv group. A further analysis according to the official regional division—even though the division has low statistical power[80]—shows a clear regional difference of thyroid cancer occurrence (per million) in the second round results: 49.2, 25.7, 19.6 and 15.5 in the evacuation zone, Hamadori, Nakadori, and Aizu, respectively.[81],[xvii] This regional difference, i.e. dose-response, contradicts the official claim dismissing a relationship between the high prevalence of thyroid cancer and radiation exposure.

Also, it should be noted that the individual external dose estimates are based on a voluntary, questionnaire survey with a low response rate of 26.4%, hardly representative of the prefecture.

Officials also refer to the 3-prefecture study to claim no geographical difference. However, as discussed earlier under the section, Other thyroid cancer data, the 3-prefecture study is an inappropriate control due to unmatched age range and sex distribution as well as the small size of the study cohort leading to a high margin of error.[26]

5.    Driver mutation patterns
Different driver mutation patterns—dominance of BRAF point mutation in Fukushima vs. RET/PTC gene arrangement in Chernobyl—does not necessarily rule out radiation effects. Reasons are clearly stated by Gerry Thomas, a British molecular pathologist, in Chapter 12of the very book the official claims are laid out[82]: “RET rearrangement and BRAF mutation are not related to exposure to radiation, but show a strong association with age of the patient at operation.” That is, RET gene arrangements—often seen in Chernobyl and ascribed to radiation exposure—are actually not related to radiation but to the morphology of PTC which in turn is associated with the age of the patient. RET gene arrangements are not unique to radiation-induced thyroid cancer[83] and may be related to the dietary iodine status.[84] BRAF V600E point mutation is more commonly seen in adults and Asian populations[85] and also related to the dietary iodine status.[86] As a matter of fact, 40 percent of 62 thyroid cancer cases diagnosed in the Ukrainian-American study had no known mutation including RET/PTC and BRAF.[87]  

6.    Pathological characteristics
By the same token, the absence of the solid variant PTC in Fukushima (at least officially[xviii])—the only pathological characteristic that purportedly sets Fukushima apart from Chernobyl—most likely simply reflects different age distributions that are inappropriately compared.

As described in the section above, the morphology of PTC is associated with the age of the patient, and the solid variant, common in Chernobyl, is seen in younger children. In Fukushima, reclassification of poorly differentiated thyroid cancer in accordance with updated diagnostic guidelines supposedly added 2 cases of the solid variant PTC to the morphological profile. However, officials have not publicized this change, perhaps to keep the story straight in their favor.

Officials have maintained the age distributions are different in Chernobyl and Fukushima, albeit over different post-accident time periods. In Chernobyl many cases were diagnosed in children younger than 4 or 5 at exposure, but this wasn’t seen until 4-5 years after the accident.

In summary, there is an interrelationship among age distributions, tumor morphology, and oncogenic profiles. In regards to exposure doses, potential underestimation and lack of data create large uncertainties.   

Fukushima and Chernobyl are indeed different, but the differences so far are not definitive enough to claim no radiation effects. Rather, the differences merely underscore the very fact they are different datasets. This misleading emphasis on “differences” has boomeranged by revealing logical inconsistencies.

Conclusive remarks
Future of the TUE is a controversial topic. FMU officials who claim overdiagnosis seem to be interested in reducing its scale and facilitating the opt out process in order to lessen psychosocial impacts of cancer diagnosis.[88] Recently, U.S. Preventive Task Force Services (USPTFS) recommended against thyroid cancer screening in adults but an exception was made for those with a history of radiation exposure.[89] The SHAMISEN project by EU recently issued recommendations  on health surveillance after a nuclear accident including a recommendation against a systematic thyroid cancer screening.[90] FMU has posted these recommendation on the English website,[91] implying its endorsement. Meanwhile, Suzuki, an FMU thyroid surgeon, advocates a long-term continuance of the TUE. Changing the course of the TUE seems premature when the second round results have not even been properly analyzed. With FMU’s transparency as well as scientific and data integrity in question, it is critical for a truly independent analysis to be conducted by qualified experts, based on the latest evidence.

[i] Scientific validity of establishing a baseline in the exposed population is unclear.
[ii] Confirmatory examinations from the second and third rounds might be simultaneously ongoing, or there could be significant delays in conducting confirmatory examinations due to logistical issues such as the lack of manpower. Originally scheduled screening periods are essentially spread over a longer time period, overlapping with the next round of screening. A precise interpretation of results from each round of screening might be nearly impossible.
[iii] This cohort includes those who were exposed in utero.  The cohort coverage reflects a Japanese school year because the TUE is conducted in school settings for elementary and middle schools.
[iv] Conducted every 2 years up to age 20, the TUE transitions at age 25 to milestone screenings to be conducted every 5 years. Some residents are beginning to participate in the age 25 milestone screening, and if they have never participated in the TUE, their milestone screening results will be added to the second round screening results. Thus the number of the second round screening participants is expected to increase even though the screening period technically ended in March 2016.
[v] The Diagnostic Criteria Subcommittee consists of members from the following seven organizations: Japan Thyroid Association; Japan Association of Endocrine Surgeons; Japan Association of Thyroid Surgery; The Japan Society of Ultrasonics in Medicine; The Japan Society of Sonographers; The Japanese Society for Pediatric Endocrinology; and Japan Association of Breast and Thyroid Sonology. The minutes of the proceeding (in Japanese) have revealed that the Diagnostic Criteria Subcommittee have met regularly behind closed doors where pre-released versions of the results were discussed amongst thyroid experts whose names are not publicized. (Accessible at
[vi] “Cysts” in the TUE are said to be colloid or simple cysts with no malignant potential: cysts with any solid components are classified as “nodules” by the size of the cysts themselves. In other words, a 20.0 mm cyst with a solid component would be classified as a 20.0 mm nodule and thus placed in the B category.
[vii] Japan’s clinical guidelines recommend hemithyroidectomy with prophylactic lymph node dissection unless total thyroidectomy is absolutely indicated.
[viii] Japan’s own clinical guidelines on cancers use essentially the same classification as the TNM classification, with the exception of the "Ex" notation which refers to the degree of extension outside the thyroid capsule: Ex1, equivalent to T3, means minimal extension (example: extension to sternothyroid muscle or perithyroid soft tissues); and Ex2, equivalent to T4, means further extension.
[ix] Review of Suzuki’s presentation video ( shows that 49 cases were pT3 due to minimal extrathyroidal extension, i.e. pEx1, rather than tumor > 4 cm limited to the thyroid .
[x] Numbers in parentheses denote the number of cases which do not add up to 33 because some cases apparently meet more than 2 surgical indications listed.
[xi] If the screening prevalence from the first round were indeed the true baseline for Japanese children and no different than the prevalence in the 3 prefecture study, it would suggest nationwide occurrence of pediatric thyroid cancer of similar prevalence as well as stages of cancer progression.
[xii] This document is available only in Japanese, but English translation is provided on the author’s blog post
[xiii] A document dated April 1, 2011 refers to an opinion of Yoshiharu Yonekura, president of the Japan National Institute of Radiological Sciences and the 2015-2016 chair of the United Nations Scientific Committee on the Effects of Atomic Radiation, that the follow-up with a thyroid counter was not warranted (Supplementary document 23 on page 74 of reference 62).
[xiv] The final count from the first round, which is what is referred here, is 116 cases, while Williams mentions 110 and Takamura et al. 113 cases.
[xv] Municipalities wholly or partly in the 20 km zone are included in the middle dose area. UNSCEAR 2013 shows some thyroid dose estimates in the 20 km zone to be higher than some municipalities designated as the middle dose area. 
[xvi] External dose estimates are based on a voluntary, questionnaire survey with a low response rate of 26.4%—hardly representative of the residents. 
[xvii] These numbers can be verified by analyzing data presented in Table 10 of the latest report on the second round, Municipalities can be divided into 4 groups according to the original analysis of the first round shown in Table 9 of this report, For reference, the numbers for the second round presented in the main text can be compared with those in the second row from the bottom in Table 9 from the first round report.
[xviii] In Fukushima, reclassification of poorly differentiated thyroid cancer in accordance with updated diagnostic guidelines supposedly added 2 cases of the solid variant PTC to the morphological profile.

[1] Overview of the Fukushima Health Management Survey. Fukushima Medical University Radiation Medical Sciences Center website. Accessed August 1, 2017
[2] Yasumura S, Hosoya M, Yamashita S, et al. Study protocol for the Fukushima Health Management Survey. Journal of Epidemiology. 2012;22(5):375-383. doi:10.2188/jea.JE20120105
[3] Support of the Fukushima Health Management Survey. Ministry of the Environment website. Accessed August 1, 2017. (in Japanese)
[4] Cost of the Fukushima Health Management Survey. Access-info Clearinghouse Japan website. Posted June 6, 2013. Accessed August 1, 2017. (in Japanese)
[5] Thyroid Ultrasound Examination (Supplemental Report of the FY 2016 Survey, Preliminary Baseline Screening).
[6] Report of Second-Round Thyroid Ultrasound Examinations (First Full-Scale Thyroid Screening Program).
[7] Report of Third-Round Thyroid Ultrasound Examinations (Second Full-Scale Thyroid Screening Program).
[8] The Prefectural Oversight Committee Meeting for Fukushima Health Management Survey, Office of International Cooperation, Radiation Health Medical Science Center, Fukushima Medical University.
[9] Ohtsuru A, Midorikawa S, Suzuki S, Shimura H, Matsuzuka T, Yamashita S. Five-year interim report of thyroid ultrasound examinations in the Fukushima Health Management Survey. In Yamashita S & Thomas G, eds. Thyroid cancer and nuclear accidents. Academic Press; 2017:145-153.
[10] Suzuki S. The features of childhood and adolescent thyroid cancer after the Fukushima nuclear power plant accident. In Yamashita S & Thomas G, eds. Thyroid cancer and nuclear accidents. Academic Press; 2017:155-163.
[11] Minutes of proceedings, The 8th Prefectural Oversight Committee Meeting for Fukushima Health Management Survey. (in Japanese)
[12] Thyroid Ultrasound Examination, The 8th Prefectural Oversight Committee Meeting for Fukushima Health Management Survey.
[13] Thyroid Ultrasound Examination, The 11th Prefectural Oversight Committee Meeting for Fukushima Health Management Survey.
[14] Thyroid Ultrasound Examination (Full-Scale Thyroid Screening Program). The 17th Prefectural Oversight Committee Meeting for Fukushima Health Management Survey.
[15] Thyroid Ultrasound Examination, The 27th Prefectural Oversight Committee Meeting for Fukushima Health Management Survey.
[16] Hiranuma, Y. Fukushima Prefecture and Fukushima Medical University Fail to Report a Thyroid Cancer Case. Fukushima Voice Version 2e. March 31, 2017. Accessed August 18, 2017.
[17] Q&A regarding the Thyroid Ultrasound Examination. Radiation Medical Science Center,  Fukushima Medical University. (in Japanese)
[18] Suzuki S, Suzuki S, Fukushima T, Midorikawa S, Shimura H, Matsuzuka T, et al. Comprehensive survey results of childhood thyroid ultrasound examinations in Fukushima in the first four years after the Fukushima Daiichi nuclear power plant accident. Thyroid. 2016;26(6):843-851. doi:10.1089/thy.2015.0564.
[19] Ohira T, Takahashi H, Yasumura S, Ohtsuru A, Midorikawa S, Suzuki S, et al. Comparison of childhood thyroid cancer prevalence among 3 areas based on external radiation dose after the Fukushima Daiichi nuclear power plant accident: The Fukushima health management survey. Medicine. 2016;95(35):e4472. doi: 10.1097/MD.0000000000004472.
[20] Suzuki S. Childhood and adolescent thyroid cancer after the Fukushima nuclear power plant accident. Oral presentation at: The Fifth International Expert Symposium in Fukushima on Radiation and Health: Chernobyl+30, Fukushima+5: Lessons and Solutions for Fukushima’s Thyroid Question; September 26, 2016. Available on Accessed July 25, 2017.
[21] Hiranuma, Y. Clinicopathological Findings of Fukushima Thyroid Cancer Cases: October 2017. Fukushima Voice Version 2e. October 9, 2017. Accessed August 18, 2017.
[22] Suzuki S, Suzuki S, Iwadate M, Tachiya Y, Ashizawa M, Ookouchi C, et al. Ultrasound findings of childhood thyroid cancer. Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery. 2017;34(1):7-16.
[23] Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Japanese Journal of Clinical Oncology. 2015;45(9):884-91. Accessed July 30, 2017.
[24] Hayashida N, Imaizumi M, Shimura H, Okubo N, Asari Y, Nigawara T, et al. Thyroid ultrasound findings in children from three Japanese prefectures: Aomori, Yamanashi and Nagasaki. PLoS ONE. 2013;8(12): e83220.
[25] Hayashida N, Imaizumi M, Shimura H, et al. Thyroid ultrasound findings in a follow-up survey of children from three Japanese prefectures: Aomori, Yamanashi and Nagasaki. Scientific Reports. 2015;5(1). doi:10.1038/srep09046.
[26] Shibuya K, et al. Time to reconsider thyroid cancer screening in Fukushima. The Lancet. 2014;383(9932):1883-1884.
[27] Hiranuma Y.  Professor Tsuda’s replies to criticisms regarding the Okayama University study, Part 2. October 30, 2015. Fukushima Voice Version 2. Accessed August 18, 2017. (in Japanese)
[28] Tsuda T, Tokinobu A, Yamamoto E, Suzuki E. Thyroid cancer detection by ultrasound among residents ages 18 years and younger in Fukushima, Japan: 2011 to 2014. Epidemiology. 2016;27(3):316-322. doi: 10.1097/EDE.0000000000000385.
[29] Jorgensen, TJ. Re: Thyroid cancer among young people in Fukushima. Epidemiology. 2016;27(3):e17. doi: 10.1097/EDE.0000000000000465.
[30] Takamura N. Re: Thyroid cancer among young people in Fukushima. Epidemiology. 2016;27(3):e18. doi: 10.1097/EDE.0000000000000464.
[31] Körblein, A. Re: Thyroid cancer among young people in Fukushima. Epidemiology. 2016;27(3):e18-e19. doi: 10.1097/EDE.000000000000046.
[32] Suzuki S. Re: Thyroid cancer among young people in Fukushima. Epidemiology. 2016;27(3):e18-e19. doi: 10.1097/EDE.0000000000000462.
[33] Shibata, Y. Re: Thyroid cancer among young people in Fukushima. Epidemiology. 2016;27(3):e19-e20. doi: 10.1097/EDE.0000000000000461.
[34] Wakeford R, Auvinen A, Gent RN, Jacob P, Kesminiene A, Laurier D, et al. Re: Thyroid cancer among young people in Fukushima. Epidemiology. 2016;27(3):e20-e21. doi: 10.1097/EDE.0000000000000466.
[35] Takahashi H, Ohira T, Yasumura S, Nollet KE, Ohtsuru A, Tanigawa K, et al. Re: Thyroid cancer among young people in Fukushima. Epidemiology. 2016;27(3):e21. doi: 10.1097/EDE.0000000000000467.
[36] Tsuda T, Tokinobu A, Yamamoto E, Suzuki E. The authors respond. Epidemiology. 2016;27(5):e36. doi: 10.1097/EDE.0000000000000468.
[37] Katanoda K, Kamo K-I, Tsugane S. Quantification of the increase in thyroid cancer prevalence in Fukushima after the nuclear disaster in 2011—a potential overdiagnosis? Japanese Journal of Clinical Oncology. 2016;46(3):284-286. doi:10.1093/jjco/hyv191.
[38] Tsugane S. The estimated number of prevalent cases of thyroid cancer in Fukushima prefecture. The Fourth Session of the Thyroid Examination Assessment Subcommittee of the Prefectural Oversight Committee Meeting for the Fukushima Health Management Survey. November 11, 2014.
[39] Minutes of Proceedings, The 26th Oversight Committee Meeting for  Fukushima Health Management Survey. February 20, 2017. (in Japanese)
[40] Hogan AR,  Zhuge Y, Perez EA, Koniaris NG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. Journal of Surgical Research. 2009;156(1):167-172.
[41] Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. British Journal of Cancer. 1995;72(3):777-783.
[42] Williams ED, Abrosimov A, Bogdanova T, et al. Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid. 2008;18(8):847-852. doi:10.1089/thy.2008.0039.
[43] Bogdanova TI, Saenko VA, Hirokawa M, et al. Comparative histopathological analysis of sporadic pediatric papillary thyroid carcinoma from Japan and Ukraine. Endocrine Journal. 2017. doi:10.1507/endocrj.ej17-0134.
[44] Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26(11):1535-1540. doi:10.1089/thy.2016.0075.
[45] Howard, J. Minimum latency & types or categories of cancer. World Trade Center Health Program. Revised January 6, 2015. Accessed July 30, 2017
[46] Barcellos-Hoff MH, Blakely EA, Burma S, et al. Concepts and challenges in cancer risk prediction for the space radiation environment. Life Sciences in Space Research. 2015;6:92-103. doi:10.1016/j.lssr.2015.07.006.
[47] Fry RJM, Ley RD, Grube D, Staffeldt E. Studies on the multistage nature of radiation carcinogenesis.
[48] Niwa, O. Epigenetic mechanism of radiation carcinogenesis (NIRS-M--106). Kobayashi, S. (Ed.). Japan. 1995: 193-198.
[49] Smith MT, Guyton KZ, Gibbons CF, et al. Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environmental Health Perspectives. 2016;124(6):713-721. doi:10.1289/ehp.1509912.
[50] Desouky O, Ding N, Zhou G. Targeted and non-targeted effects of ionizing radiation. Journal of Radiation Research and Applied Sciences. 2015;8(2):247-254. doi:10.1016/j.jrras.2015.03.003.
[51] Barcellos-Hoff MH, Nguyen DH. Radiation carcinogenesis in context: how do irradiated tissues become tumors? Health physics. 2009;97(5):446-457. doi:10.1097/HP.0b013e3181b08a10.
[52] Barcellos-Hoff MH, Adams C, Balmain A, et al. Systems biology perspectives on the carcinogenic potential of radiation. Journal of Radiation Research. 2014;55(Suppl 1):i145-i154. doi:10.1093/jrr/rrt211
[53] Kim E, Kurihara O, Suzuki T, Matsumoto M, Fukutsu K, Yamada Y, Sugiura N, Akashi M. Screening survey on thyroid exposure for children after the Fukushima Daiichi Nuclear Power Station accident. In: Proceedings of the 1st NIRS Symposium on Reconstruction of Early Internal Dose in the TEPCO Fukushima Daiichi Nuclear Power Station Accident. National Institute of Radiological Sciences. Chiba, Japan, July 2012. NIRS-M-252 2012:59–66. Available on Accessed July 30, 2017. (in Japanese)
[54] study2007. For re-assessment of the early childhood thyroid screening: factors leading to underestimation. Kagaku. 2014;84(4):406-414. (in Japanese)
[55] Nuclear Safety Commission. Circumstances surrounding the pediatric thyroid survey. Published September 13, 2012. Accessed August 27, 2017. (in Japanese)
[56] Yamashita S. Fear is a killer: Nuclear expert reveals radiation’s real danger. New Scientist. 2017;3125. Accessed July 18, 2017.
[57] Results of the inspection on radioactivity level in raw milk. Excel file for March 11, 2011-March 31, 2011. Ministry of Agriculture, Forestry and Fisheries. Accessed August 24, 2017.
[58] Foods exceeding the regulatory limits: deal with them calmly. NHK. March 19, 2011. Accessed August 5, 2017. (in Japanese)
[59] Kim E, Tani K, Kunishima N, Kurihara O, Sakai K, Akashi M. Estimation of early internal doses to Fukushima residents after the nuclear disaster based on the atmospheric dispersion simulation. Radiation Protection Dosimetry. 2016;171(3):398–404.
[60] Ohba T, Hasegawa A, Kobayagawa Y, Kondo H, Suzuki G. Body surface contamination levels of residents under different evacuation scenarios after the Fukushima Daiichi nuclear power plant accident. Health Physics. 2017;113(3): 175-182. doi: 10.1097/HP.0000000000000690.
[61] Yamashita S. Adolescent thyroid cancer after the Fukushima nuclear power plant accident: mass screening effect of a real increase? ASCO Daily News. Published May 26, 2016. Accessed July 30, 2017.
[62] Bithell JF, Stewart AM. Pre-natal irradiation and childhood malignancy: a review of British data from the Oxford Survey. British Journal of Cancer. 1975;31(3):271-287.
[63] Cardis E, Vrijheid M, Blettner M, Gilbert E, Hakama M, Hill C, et al. Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ. 2005;331.
[64] Spycher BD, Lupatsch JE, Zwahlen M, Röösli M, Niggli F, Grotzer MA, Rischewski J, Egger M, Kuehni CE, for the Swiss Pediatric Oncology Group and the Swiss National Cohort. Background ionizing radiation and the risk of childhood cancer: a census-based nationwide cohort study. Environ Health Perspect. 2015;123:622–628.
[65] Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, et al. Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013;346:f2360.
[66] Leuraud K, Richardson DB, Cardis E, Daniels RD, Gilles M, O”Hagan JA. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. The Lancet Hematology. 2015;2(7):e276–e281.
[67] Richardson DB, Cardis E, Daniels RD, Gillies M, O’Hagan JA, Hamra GB, et al. Risk of cancer from occupational exposure to ionising radiation: retrospective cohort study of workers in France, the United Kingdom, and the United States (INWORKS). BMJ. 2015;351:h5359.
[68] Veiga LHS, Holmberg E, Anderson H, Pottern L, Sadetzki S, Adams MJ, et al. Thyroid Cancer after Childhood Exposure to External Radiation: An Updated Pooled Analysis of 12 Studies. Radiation Research. 2016;185(5):473-484.
[69] Tsubokura M, Nomura S, Watanobe H, Nishikawa Y, Suzuki C, Ochi S, et al. Assessment of nutritional status of iodine through urinary iodine screening among local children and adolescents after the Fukushima Daiichi nuclear power plant accident. Thyroid. 2016;26(12):1778-1785.
[70] Takamura N, Orita M, Saenko V, Yamashita S, Nagataki S, Demidchik Y. Radiation and risk of thyroid cancer: Fukushima and Chernobyl. The Lancet. 2016;4(8):647.
[71] Yamashita S & Siemann M. Workshop on radiation and cancer, co-chair’s summary. Released on February 23, 2014
[72] Williams D. Thyroid growth and cancer. Eur Thyroid J. 2015;4:164-173.
[73] Tronko MD, Saenko VA, Shpak VM, Bogdanova TI, Suzuki S, Yamashita S. Age distribution of childhood thyroid cancer patients in Ukraine after Chernobyl and in Fukushima after the TEPCO-Fukushima Daiichi NPP accident. Thyroid. 2014;24(10):1547-1548. doi:10.1089/thy.2014.0198.
[74] Hiranuma Y. Misrepresented risk of thyroid cancer in Fukushima. The Lancet. 2016;4(12):970.
[75] WHO. Health risk assessment from the nuclear accident after the 2011 Great East Japan earthquake and tsunami, based on a preliminary dose estimation. 2013.
[76] UNSCEAR 2013 Report Vol. I: Sources, effects, and risks of ionizing radiation. Annex A: Levels and effects of radiation exposure due to the nuclear accident after the 2011 great east-Japan earthquake and tsunami. Attachment C-18: Doses to evacuees in Japan for the first year.
[77] UNSCEAR 2013 Report Vol. I: Sources, effects, and risks of ionizing radiation. Annex A: Levels and effects of radiation exposure due to the nuclear accident after the 2011 great east-Japan earthquake and tsunami. Attachment C-16: Thyroid doses in Japan for the first year.
[78] Hosoda M, Tokonami S, Tazoe H, Sorimachi A, Monzen S, Osanai M, et al. Activity concentrations of environmental samples collected in Fukushima Prefecture immediately after the Fukushima nuclear accident. Scientific Reports. 2013;3(2283). doi:10.1038/srep02283.
[79] Makino J. Scientific literacy after 3.11, No.57. Kagaku. 2017;87(8):709-711. (in Japanese)
[80] Hamaoka Y. Issues regarding the thyroid examination in Fukushima. Kagaku. 2016;86(11):1090-1101. (in Japanese)
[81] Makino J. Scientific literacy after 3.11, No.58. Kagaku. 2017;87(9):830-833. (in Japanese)
[82] Thomas G. Somatic genomics of childhood thyroid cancer. In Yamashita S & Thomas G, eds. Thyroid cancer and nuclear accidents. Academic Press; 2017:121-132.
[83] Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57(9):1690-1694.
[84] Williams ED,  Abrosimov A, Bogdanova T, Demidchik EP, Ito M, LiVolsi V, et al. Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid. 2008;18(8):847-852.
[85] Bychikov A. Prevalence of BRAFV600E mutation in Asian patients with thyroid cancer. Malays J Pathol. 2017;39(1):95-96.
[86] Song YS, Lim JA, Park YJ. Mutation Profile of Well-Differentiated Thyroid Cancer in Asians. Endocrinology and Metabolism. 2015;30(3):252-262. doi:10.3803/EnM.2015.30.3.252.
[87] Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, Zurnadzy LY, et al. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer. 2013;119: 1792–1799. doi:10.1002/cncr.27893.
[88] Midorikawa S, Ohtsuru A, Suzuki S, Tanigawa K, Ohto H, Abe M, Kamiya K. Psychosocial impact of the Thyroid Examination of the Fukushima Health Management Survey. In Yamashita S & Thomas G, eds. Thyroid cancer and nuclear accidents. Academic Press; 2017:165-173.
[89]  US Preventive Services Task Force. Screening for Thyroid CancerUS Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(18):1882–1887. doi:10.1001/jama.2017.4011
[90] Oughton D, Albani V, Barquinero F, Chumak V, Clero E, Crouail P , et al on behalf of the SHAMISEN Consortium. Recommendations and procedures for preparedness and health surveillance of populations affected by a radiation accident. July 2017.
[91] SHAMISEN recommendation booklet is available. Office of International Cooperation, Radiation Health Medical Science Center, Fukushima Medical University. Published August 7, 2017. Accessed August 10, 2017.


Popular posts from this blog

Fukushima Thyroid Examination May 2015: 103 Thyroid Cancer Cases Confirmed, 5 in the Second Round Screening

The Nineteenth Prefectural Oversight Committee for Fukushima Health Management Survey convened in Fukushima City, Fukushima Prefecture, on May 18, 2015, releasing the latest results of thyroid examination, consisting of Initial Screening or the first round screening (originally scheduled to be conducted from October 2011 to March 2014, but actually still ongoing) and Full-Scale Screening or the second round screening (beginning April 2014). It has been 3 months since the last committee meeting on February 12, 2015, and the latest results include 3 more months worth of data confirmed as of March 31, 2015.

An official English translation of the results is now available here.

As of March 31, 2015, there are 16 more (12 from the first round and 4 from the second round) confirmed cancer cases, all papillary thyroid cancer, and 9 more (2 from the first round and 7 from the second round) newly suspicious cases. The number of confirmed cancer cases now totals 103 (98 from the first round and 5…

"Strict" Management of the Fukushima Health Management Survey Data by Fukushima Medical University

The Interim Report released in March 2016 by the Oversight Committee for Fukushima Health Management Survey called for the need to establish the rules of management and provision of the data so it can be widely utilized by domestic and international experts. Accordingly, the Subcommittee to Review Provision of Data for the Purpose of Academic Research met in Fukushima City, Fukushima, for the first time on May 31, 2016. Subcommittee members were selected by the Fukushima prefectural government in order to address the role of the subcommittee in establishing technical rules in provision of data and include specialists in epidemiology, information technology, law, and legal sociology. Also included are members of the Oversight Committee for Fukushima Health Management Survey, Shoichiro Tsugane and Hokuto Hoshi, and the Health Survey Support Department Head and the Department of Epidemiology Chair at Fukushima Medical University, Tetsuya Ohira, representing the Fukushima Health Managemen…

Translation of a News Article: "Thyroid Cancer--A Few Percent Recurred After Surgeries"

On September 27, 2016, an article titled "Thyroid Cancer: A Few % Recurred After Surgeries" appeared on the website of NHK Fukushima Station. The URL shows an error message because the article is no longer shown online due to a short posting time on local station websites: newer articles push older ones off the slot, and this article, posted at 1:05 pm likely was pushed off the website as the evening news articles rolled in. NHK does not maintain archives of its articles on their website. Luckily, the article was archived here. English translation is provided below, and more detailed information on the surgical cases is available in this post.


Thyroid Cancer: A Few Percent Recurred After Surgeries

A physician who has been conducting surgeries on children diagnosed with thyroid cancer revealed for the first time that there has been a few percent of the cases recurred after surgery. These cancer cases were diagnosed during the Thyroid Examination conducted by Fukushima Pre…